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BACKGROUND  
Biology based treatment reduction, i.e. surgery alone also in case of not totally resected tumors, was 
advised in neuroblastoma patients with localized resectable disease without MYCN amplification. 
However, whether the genomic background of these tumors may influence outcome was unknown 
and therefore scrutinized in a meta-analysis comprising two prospective therapy studies and a 
‘validation’ cohort. 
PATIENTS AND METHODS 
Diagnostic samples were derived from 406 INSS stages 1/2A/2B tumors from three cohorts: 
LNESGI/II and COG. Genomic data were analyzed in two age groups (cut-off: 18 months) and quality 
controlled by the SIOPEN Biology Group.  
RESULTS 
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In both patient age groups stage 2 tumors led to similarly reduced event-free survival (5y-EFS: 
83+3% versus 80+4%), but overall survival was only decreased in patients >18m (5y-OS: 97+1% 
versus 87+4%; p=0.001). In the latter age subgroup, only tumors with SCA led to relapses, with 11q 
loss as the strongest marker (5y-EFS: 40+15% versus 89+5%; p<0,001). Below 18m, EFS but not OS 
was decreased only in case of 1p loss (5y-EFS: 62+13% versus 85+3%; p=0,041). SCAs were 
associated with worse OS only in patients >18m but not <18m. 
CONCLUSION 
The tumor genomic make-up of resectable non-MYCN amplified stage 2 neuroblastomas has a 
distinct age-dependent prognostic impact in neuroblastoma patients. While in the younger age 
group tumors with unfavourable (SCA) and favorable genetics showed relapses, both without 
worsening OS, in the older age group only tumors with unfavorable genetics led to relapses and 
decreased OS.  
 
